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Objective: The TGF-b pathway plays a central role in joint development with polymorphism in TGF-b
pathway genes implicated in osteoarthritis susceptibility. One association is to rs12901499, within intron
1 of SMAD3. Since rs12901499 is not in linkage disequilibrium with a non-synonymous polymorphism, it
is likely the association is operating by inﬂuencing expression of SMAD3.
Design: Using tissues from the joints of primary osteoarthritis patients who had undergone joint
replacement we measured the overall expression of SMAD3 by quantitative real-time PCR. We also
measured allelic expression of SMAD3 using these tissues and vascular smooth muscle cells from patients
with aneurysms and osteoarthritis syndrome, a rare condition featuring early-onset osteoarthritis. We
tested the functional effect of SNPs in vitro using luciferase assays and assessed association with oste-
oarthritis using a large osteoarthritis caseecontrol dataset.
Results: We observed that genotype at rs12901499 did not correlate with overall SMAD3 expression or
allelic expression. However, genotype at a 30UTR SNP, rs8031440, did correlate with SMAD3 expression in
cartilage (P ¼ 0.005) which was supported by allelic expression data showing that the G allele correlated
with decreased SMAD3 expression in joint tissues and vascular smooth muscle cells. This G allele was
underrepresented in osteoarthritis cases vs controls (P ¼ 0.027, odds ratio ¼ 0.921). rs8031440 is in
perfect linkage disequilibrium with ﬁve other SMAD3 30UTR SNPs and our luciferase analysis identiﬁed
rs3743342 and rs12595334 as being functional.
Conclusion: SMAD3 is subject to cis-acting regulatory polymorphism in the tissues of relevance to both
primary osteoarthritis and the aneurysms-osteoarthritis syndrome.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Introduction
The TGF-b signalling pathway plays a critical role in joint
development and maintenance and there is accumulating evidence
of involvement of this pathway in osteoarthritis (OA) aetiology1.
Genetic studies have contributed to this evidence, with OA risk
alleles reported in the genes GDF5, ASPN and SMAD32.
SMAD3 codes for the protein mothers against decapentaplegic
homolog 3, an intracellular molecule that translocates the TGF-b: J. Loughlin, Newcastle Uni-
al Research Group, 4th Floor
ramlington Place, Newcastle
ine), john.loughlin@ncl.ac.uk
ternational. Published by Elsevier Lsignal to the nucleus instigating gene transcription. Smad3-
knockout mice develop a degenerative joint disease resembling
OA3 whilst nonsense, missense and frame-shift mutations of
SMAD3 can result in the aneurysms and osteoarthritis syndrome
(AOS), which involves thoracic aortic aneurysms and dissections
with early-onset OA4,5. In 2010 it was reported that the single
nucleotide polymorphism (SNP) rs12901499, located in intron 1 of
SMAD3, was associated with common primary hip and knee OA in a
European cohort6, with P < 4.5  106.
As more susceptibility loci are identiﬁed for human diseases it
has become apparent that the majority of risk alleles contribute to
disease occurrence by inﬂuencing the expression of nearby genes,
by either regulating transcription or the stability of their tran-
scripts7. These are known as cis-acting expression quantitative trait
loci or cis-eQTLs. Since rs12901499 is not in linkage disequilibrium
(LD) with a non-synonymous polymorphism, we hypothesised thattd. Open access under CC BY-NC-ND license.
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In this manuscript we have used a number of experimental tech-
niques to test this hypothesis. We were also keen to assess whether
any such cis-eQTL was operating in tissues of relevance to AOS, thus
potentially providing a pathological link between common OA and
the syndrome.
Materials and methods
Patients
Joint tissues were obtained from patients undergoing total hip
replacement (THR) or total knee replacement (TKR) for primary OA,
as described previously8,9. The radiological stage of the disease was
a Kellgren and Lawrence grade of 2 or more. Cases of inﬂammatory
arthritis, post-traumatic or post-septic arthritis or suggestive of
skeletal or developmental dysplasias were excluded. The tissues
collected were articular cartilage, infrapatellar fat pad, meniscus,
and synovium. The Newcastle and North Tyneside research ethics
committee granted ethical approval for the tissue collection (REC
reference number 09/H0906/72) and informed consent was ob-
tained from each donor. Additional patient details are listed in
Supplementary Tables S1 and S2.
Nucleic acid extraction
On the day of surgery, tissue was snap-frozen at 80C. Between
0.5 and 1.0 g of frozen tissue was ground to a powder using a Retsch
mixermill 200 (Retsch Limited, Leeds, UK) under liquid nitrogen. DNA
and RNAwere extracted using an Omega EZNADNA/RNA Isolation Kit
(Omega Bio-Tek, Norcross, USA) andquantiﬁed using aNanoDropND-
1000Spectrophotometer (NanoDropTechnologies,Wilmington,USA).
Gene expression
Initially 2 mg of RNA was reverse transcribed using the Super-
Script First-Strand cDNA synthesis kit (Invitrogen, Paisley, UK).
SMAD3 expression was assessed by quantitative PCR and measured
relative to the average expression of the housekeeping genes
HPRT1, GAPDH and 18S. For each cDNA sample three pipetting
replicates were performed for SMAD3 and the housekeeping genes.
We combined the housekeeper cycle threshold (Ct) values and
derived the mean Ct using this to compare against SMAD3
expression. Reactions were carried out using an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Paisley, UK), and
PrimeTime Mini qPCR Assays (Integrated DNA Technologies, Iowa,
USA). Primer and probe sequences are listed in Supplementary
Table S3(A). Relative expression levels compared to the house-
keepers were calculated using the 2DCt method.
Transcript SNP selection and SNP genotyping
Using public databases the transcript sequence of SMAD3 was
searched for common SNPs (minor allele frequencies >10%). The
30UTR SNP rs8031440 was chosen for analysis. This SNP has a minor
allele frequency of 0.26 and pairwise r2 and D0 values of 0.01 and
0.21, respectively, relative to rs12901499. SNP genotyping was
carried out by restriction fragment length polymorphism (RFLP)
analysis. The primer sequences and the restriction enzymes are
listed in Supplementary Table S3(B).
Allelic expression imbalance analysis (AEI)
cDNA from patients heterozygous at the transcript SNP
rs8031440 were analysed for AEI using a readymade TaqMangenotyping assay (Applied Biosystems) for use with the ABI PRISM
7900HT Sequence Detection System (Applied Biosystems). The
assay employs a probe labelled with FAM or VIC speciﬁc to each of
the alleles of an SNP. Real-time PCRwas carried out according to the
manufacturer’s instructions. The reactions were performed in ﬁve
replicates and the allele ratios were calculated using the formula
(2FAM Ct/2VIC Ct). The allelic ratios were calculated for genomic
DNA and cDNA. The average allelic ratio of the genomic DNA
(representing the assumed 1:1 ratio between alleles) was then used
to normalise the cDNA allelic ratios and thus account for differences
in ﬂuorescent yield and incorporation speciﬁc to an assay. The ca-
pacity for the assay to discriminate between alleles was veriﬁed
using a standard curve performed on cDNA and DNA of varying
allelic ratios (data not shown).
Association with OA
We assessed SNP rs8031440 for evidence of association to OA
using data from the arcOGEN study, a large GWAS conducted in the
UK on population controls and cases with severe OA of the hip or
knee, 80% of whom had undergone total joint replacement10. The
array used was the Illumina 610 Quad array. rs8031440 is not on
this array so SNP rs7166081, an SNP located downstream of SMAD3
and in perfect LD (r2 ¼ 1, D0 ¼ 1) with rs8031440, was used as a
direct proxy. Since our expression studies were all performed on OA
cases who had undergone total joint replacement we assessed as-
sociation to rs8031440 using the 5804 arcOGEN OA cases who had
also undergone this procedure.
Construction of luciferase reporter plasmids
To generate the constructs for use in the luciferase reporter gene
assay, primers ﬂanked by restriction enzyme sites were designed to
amplify three DNA fragments encompassing the six 30UTR SNPs;
amplicon A containing rs8025774; amplicon B containing
rs8031440, rs8031627, and rs2278670; and amplicon C containing
rs12595334 and rs3743342. Primer sequences and restriction en-
zymes are listed in Supplementary Table S4(A). PCR products were
puriﬁed using the QIAquick PCR puriﬁcation kit (Qiagen, Hilden,
Germany) and dephosphorylated with Antarctic phosphatase (GE
Healthcare, Buckinghamshire, UK). The PCR products were cloned
into the pMIR-report vector (Promega, Southampton, UK). Positive
clones were sequenced to ensure the correct sequence of the
construct.
Site-directed mutagenesis of luciferase reporter plasmids
To generate the necessary haplotypes primers were designed to
force a base change at the relevant SNP (primer sequences are listed
in Supplementary Table S4(B)). Mutagenesis was performed using
the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technol-
ogies, Berkshire, UK) following the manufacturer’s instructions.
Cell cultures and luciferase assay
The SW1353 human chondrosarcoma cell line (ATCC, Middlesex,
UK) and the MG63 human osteosarcoma cell line (ATCC) were used
for transfection. Forty-eight hours before transfection cells were
seeded at a density of approximately 17,500 cells per well in a 48-
well plate. Cells were transfected with 500 ng DNA from the vector
constructs and 15 ng Renilla luciferase control reporter vector pRL-
TK (Promega), using ExGen 500 transfection reagent (Fermentas,
Leicestershire, UK). After 24 h the cells were lysed and luciferase
activity was determined using the Dual-Luciferase Reporter Assay
System (Promega). Luminescence was measured using a
Fig. 1. Columnar scatter plots of the quantitative expression of SMAD3 in knee OA vs
hip OA cartilage. n is the number of patients studied. The horizontal lines in each plot
represent the mean and the 95% conﬁdence interval. P-value was calculated using a
ManneWhitney U Test.
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nologies, Bad Wildbad, Germany). The luciferase activity was nor-
malised to the Renilla activity. Six technical and three biological
repeats were performed per construct.
Cell culture of aortic vascular smooth muscle cells (VSMCs)
VSMCs from aortic tissue were cultured in complete smooth
muscle cell basal medium (SmBM; Lonza, Basel, Switzerland) sup-
plemented with 5% FBS (Lonza), 0.1% human recombinant
epidermal growth factor (rhEGF; Lonza), 0.1% human recombinant
insulin, 0.2% human recombinant ﬁbroblast growth factor B (hrFGF-
B; Lonza), and 500 ml GA-100 (gentamicin sulfate/amphotericin-B;
Lonza). Cells were maintained in 10 cm tissue culture dishes coated
in 0.1% gelatin, in a humidiﬁed 5% CO2 incubator. Cells were
passaged at 80% conﬂuence. Nucleic acids were extracted from the
cells as described above.
Molecular haplotyping
Using cDNA as a template we ampliﬁed a region of SMAD3
encompassing the Arg287Trp mutation and rs8025774, which is inFig. 2. Allelic expression analysis of the 3’UTR transcript SNP rs8031440 using cDNA from ca
cDNA allelic ratio in each patient was compared to the 1:1 allelic ratio calculated from theperfect LD with rs8031440, in patients A and B. The primer se-
quences are listed in Supplementary Table S3(C). PCR was per-
formed in a 50 ml reaction and the product was cloned into the pCR-
4 TOPO vector using the TOPO TA cloning kit (Invitrogen). Colonies
were picked, grown and the extracted plasmid DNA was directly
sequenced to assess the molecular haplotype between Arg287Trp
and rs8025774/rs8031440.
Bioinformatic analysis of microRNAs binding sites
PolymiRTS (http://compbio.uthsc.edu/miRSNP), TargetScan
(http://www.targetscan.org/), MiRBase (http://www.mirbase.org/),
PicTAR (http://pictar.mdc-berlin.de/) and miRWalk (http://www.
umm.uni-heidelberg.de/apps/zmf/mirwalk/) were used to identify
sequence variations in putative miRNA binding sites and to predict
binding sites for miRNAs encompassing rs12595334 and rs3743342.
Statistical analysis
Differences in quantitative gene expression, and differences in
luciferase activity between allelic and haplotypic forms, were
assessed using a ManneWhitney U Test and the GraphPad Prism
software package (LaJolla, California, USA).
Results
SMAD3 expression in hip OA vs knee OA cartilage
We initially demonstrated expression of SMAD3 in eight joint
tissues collected from OA patients (Supplementary Figure S1). We
then compared expression of SMAD3 between hip cartilage from 16
OA patients and knee cartilage from 58 OA patients [Fig. 1]. This
revealed a signiﬁcantly lower level of SMAD3 expression in the hip
(P ¼ 0.05).
Quantitative expression of SMAD3 in cartilage stratiﬁed by genotype
at rs12901499
To determine whether SMAD3 harboured cartilage eQTLs that
correlated with the OA association signal we quantiﬁed levels of
SMAD3 expression in our OA cartilage samples and then stratiﬁed
the data by genotype at the OA associated SNP rs12902499
(Supplementary Figure S2(A)). There was no correlation between
genotype and expression (P ¼ 0.85). We repeated the analysis afterrtilage. The genotypes of the patients for the associated SNP rs12901499 are shown. The
DNA of that patient.
Fig. 3. Columnar scatter plots of the quantitative expression data of SMAD3. (A) shows
OA cartilage, (B) shows OA knee cartilage, and (C) shows OA hip cartilage, with patients
stratiﬁed by genotype at the 30UTR transcript SNP rs8031440. Due to the low frequency
of AA homozygotes at rs8031440 the analysis was performed between GG homozy-
gotes and A-allele carriers (GA and AA combined). n is the number of patients studied.
The horizontal lines in each plot represent the mean and the 95% conﬁdence interval.
P-values were calculated using a ManneWhitney U Test.
E.V.A. Raine et al. / Osteoarthritis and Cartilage 22 (2014) 698e705 701separating the knee (Supplementary Figure S2(B)) and hip
(Supplementary Figure S2(C)) cases. Again there was no correlation
in the knee cartilage (P ¼ 0.36) or the hip cartilage (P ¼ 0.31).
AEI analysis of SMAD3 in cartilage
We further investigated the possible presence of SMAD3 eQTLs
by AEI. Since rs12901499 is not a transcript SNP it could not be used
in the AEI analysis. We therefore studied patients who were het-
erozygous for rs12901499 and for the 30UTR SNP rs8031440,
enabling us to indirectly test any allelic output that correlated with
rs12901499, since if this were occurring we would expect to
observe AEI in a high proportion of these compound heterozygotes.
rs8031440was chosen because it has a reasonably highminor allele
frequency (0.26) ensuring that a large proportion of our patients
will be heterozygous and therefore suitable for the AEI analysis. We
also studied individuals who were homozygous for rs12901499 but
heterozygous for rs8031440, thus enabling us to assess whether
SMAD3 could also be subject to cis-eQTLs acting independently of
the association signal marked by rs12901499.
Cartilage from eight knee OA patients were analysed and each
demonstrated AEI, with the G allele of rs8031440 showing reduced
expression in all patients [Fig. 2 and Supplementary Table S5]. The
average fold difference was 1.31, namely the A-allele of this SNP
produced 31% more SMAD3 expression than the G allele. AEI was
also observed in fat pad, synovium and meniscus samples from an
additional six knee OA patients; the observed AEI is therefore not
cartilage-speciﬁc (Supplementary Figure S3 and Supplementary
Table S5). Seven of the 14 patients were heterozygous for
rs12901499 whilst seven were not. The most likely explanation for
our AEI result is that the 30UTR SNP rs8031440 is functional and
mediating AEI or that it is in very high LDwith the functional SNP. It
is unlikely that the OA associated SNP rs12901499 is responsible
(either directly or indirectly) for the AEI observed.
Quantitative expression of SMAD3 in cartilage stratiﬁed by genotype
at rs8031440
Having established that rs8031440 is highlighting a SMAD3
eQTL, we stratiﬁed our SMAD3 quantitative expression data by
genotype at this SNP. We observed a signiﬁcant correlation be-
tween SMAD3 expression in cartilage and rs8031440 genotype
[Fig. 3(A)], with the G allele of the SNP correlating with reduced
SMAD3 expression (P ¼ 0.005). This G allele also correlated with
reduced expression in our AEI analysis [Fig. 2]. Since this is the
second time in which we have stratiﬁed this expression data by
genotype at an SNP we applied a Bonferroni correction by multi-
plying the P by 2, giving a still signiﬁcant P-value of 0.01. We
stratiﬁed the OA patients into knee [Fig. 3(B)] and hip [Fig. 3(C)]
cases and observed a signiﬁcant correlation in the knee cases
(P < 0.001). The number of hip cases was only 16, which may have
limited our power to see an effect in this stratum.
rs3743342 and rs12595334 are functional
rs8031440 is in perfect LD (r2 ¼ 1, D0 ¼ 1) with ﬁve other
SMAD3 30UTR SNPs: rs8025774, rs8031627, rs2278670, rs12595334
and rs3743342. To assess whether rs8031440 or any of these ﬁve
other SNPs are functional we cloned fragments of the 30UTR into a
luciferase plasmid and performed reporter gene expression assays
using the SW1353 and the MG63 cell lines. We cloned three
fragments: amplicon A, containing rs8025774; amplicon B, con-
taining rs8031440, rs8031627 and rs2278670; and amplicon C,
containing rs12595334 and rs3743342. For each amplicon we
cloned both allelic forms. We did not observe any signiﬁcantdifferences in luciferase gene expression between the alleles of
rs8025774 or between the haplotypes of rs8031440-rs8031627-
rs2278670 in either SW1353 [Fig. 4(A) and (B)] or MG63
[Fig. 5(A) and (B)] cells. We did however observe a signiﬁcant
difference between the haplotypes of rs12595334-rs3743342 in
Fig. 4. Functional analysis of the six SMAD3 3’UTR SNPs in SW1353 cells. (AeC) show the results of the luciferase reporter assays for amplicons A, B and C, respectively. (D) shows
the results of the luciferase reporter assay for the four possible haplotypes (CC, CT, TT, and TC) for rs12595334 and rs3743342. Data are the fold expression relative to Renilla activity
and are shown as the mean and 95% conﬁdence intervals from three biological repeats each with six technical replicates. P-values were calculated using a ManneWhitney U Test.
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MG63, Fig. 5(C)] indicating that one, or both, of these SNPs is
inﬂuencing gene expression. Using site-directed mutagenesis we
mutated each allele of these two SNPs to create the alternative
rs12595334-rs3743342 haplotypes CT and TC and compared
luciferase activity between these and the naturally occurring TT
and CC haplotypes. Since the CC haplotype of rs12595334-
rs3743342 is in LD with the low-expressing G allele of
rs8031440, we focused our interpretation on changes to this
haplotype. In SW1353 cells, mutating rs3743342 from a C to a T
had no effect [P ¼ 0.97, Fig. 4(D)] whereas mutating rs12595334
from a C to a T signiﬁcantly increased luciferase activity [P < 0.001,
Fig. 4(D)]. In MG63 cells, mutating rs3743342 from a C to a T did
have an affect (unlike in SW1353), increasing activity [P < 0.001,
Fig. 5(D)]. Mutating rs12595334 from a C to a T also signiﬁcantly
increased luciferase activity in the MG63 cells [P < 0.001,
Fig. 5(D)]. Alternative effects were observed following changes to
the TT haplotype. However, since the CC haplotype is in LD with
the G allele of rs8031440, this luciferase data supports the patient
tissue expression data. Both rs12595334 and rs3743342 are func-
tional, with rs3743342 appearing to have a more cell-restricted
effect.
30UTRs can be the target site for gene expression regulation by
microRNAs11. We therefore performed a database search of poten-
tial microRNA binding sites encompassing rs12595334 and
rs3743342 but none were found for either allelic form of the SNPs.Genetic association with OA
We assessed whether the eQTL marked by rs8031440, and
potentially mediated by rs12595334 and rs3743342, was asso-
ciated with OA. To do this we used the arcOGEN GWAS dataset,
comprising 5804 OA cases who had undergone joint replacement
and 11,009 population controls10. Neither rs8031440, rs1259
5334 or rs3743342 are on the Illumina 610 Quad array used by
arcOGEN, nor are any of the other SMAD3 30UTRs SNPs that are in
perfect LD with them. The SNP rs7166081, which is located
downstream of SMAD3, is however on the array and is also in
perfect LD with rs8031440, rs12595334 and rs3743342. We
therefore used the association data generated for rs7166081 as a
direct proxy. This revealed that the SMAD3 eQTL showed mar-
ginal evidence of association with OA (P ¼ 0.027; Table I).
Stratiﬁcation of the arcOGEN dataset by sex, by site of OA (hip or
knee), and by sex combined with site did not enhance the as-
sociation signal, with the most signiﬁcant P-value being 0.001
(odds ratio of 0.915) for male knee cases. In all instances the C
allele of rs7166081, which is equivalent to the G allele of
rs8031440 correlating with decreased SMAD3 expression, was
less common in OA cases.
As noted in the introduction, one of the articles that stimulated
our interest in SMAD3 reported an association of rs12901499 with
hip and knee OA6, with P < 4.5  106. In the arcOGEN joint
replacement cases this SNP had a P-value of 0.003.
Fig. 5. Functional analysis of the six SMAD3 3’UTR SNPs in MG63 cells. (AeC) show the results of the luciferase reporter assays for amplicons A, B, and C, respectively. (D) shows the
results of the luciferase reporter assay for the four possible haplotypes (CC, CT, TT, and TC) for rs12595334 and rs3743342. Data are the fold expression relative to Renilla activity and
are shown as the mean and 95% conﬁdence intervals from three biological repeats each with six technical replicates. P-values were calculated using a ManneWhitney U Test.
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Finally we investigated the activity of the SMAD3 eQTL using
vascular smooth muscle cells (VSMCs) derived from aortic tissue of
AOS patients. This disease is caused by rare mutations in SMAD3
and we were keen at this stage to assess whether the eQTL was
operating in a non-joint tissue of relevance to AOS. If so, it could
potentially contribute to the interfamilial variability seen in this
disease4. We studied two patients with AOS, caused by a missense
Arg287Trp mutation in SMAD3, and a normal control individual. All
three were heterozygous for rs8031440. The control (a male born in
1955) and patient A (a male born in 1979) both demonstrated AEI
[Fig. 6], whereas patient B (a male born in 1947) did not. The AEI
observed in the control and patient A was in the same direction as
that observed in joint tissues, namely decreased expression of the G
allele of rs8031440. The allelic ratios of 1.39 (control) and 1.25
(patient A) were also comparable to those seen in the primary OA
patients (Supplementary Table S5). We conclude therefore that the
SMAD3 eQTL is also active in a tissue that is of direct relevance to
the aneurysm component of AOS.
Using cDNA as a templatewe assessed themolecular haplotypes
for the Arg287Trpmutation and rs8031440 in patients A and B. This
revealed that in both patients the low-expressing G allele of
rs8031440 was on the wild type allele. Patient B is the ﬁrst cousin
once removed of patient A and both have the heterozygous
Arg287Trp mutation. The two patients have therefore inherited theG allele of rs8031440 from a recent common ancestor. The fact that
this G allele shows reduced expression in patient B but not in pa-
tient A implies that its expression is likely to be modiﬁed by other
cis-acting effects, which may be genetic or epigenetic.
A search of the PhenGenI (http://www.ncbi.nlm.nih.gov/gap/
phegeni/) and RegulomeDB12 databases found no evidence that
rs8031440 acts as an eQTL in other tissues, implying that the eQTL
does not have a ubiquitous effect on SMAD3 expression.
Discussion
Using joint tissues from patients with primary OA we set out to
assess whether the alleles of the OA associated SMAD3 SNP
rs12901499 correlated with differences in expression of the gene,
based on our hypothesis that this may be the mechanism through
which the rs12901499 OA association is operating. We failed to ﬁnd
any evidence of such a correlation, implying that our hypothesis is
incorrect. It is possible however that the association marked by
rs12901499 is operating during development and that an investi-
gation of the joint tissues of young individuals may reveal a cor-
relation between rs12901499 and SMAD3 expression. The
collection of a sufﬁciently large number of such tissues is however
prohibitive, since young individuals do not present for joint
replacement surgery.
During our investigations we did discover a SMAD3 eQTL that
was operating in joint tissues, the ﬁrst reported case of this as far as
Table I
Association analysis of rs7166081 with OA using the arcOGEN data
Stratum Cases n Controls n C-allele frequency cases C-allele frequency controls P-value Odds ratio*
All cases 5804 11,009 0.220 0.235 0.027 0.921 (0.857e0.991)
Hip cases 3039 11,009 0.214 0.233 0.002 0.896 (0.837e0.960)
Knee cases 2164 11,009 0.221 0.233 0.077 0.932 (0.862e1.008)
Female cases 3363 5515 0.217 0.235 0.030 0.904 (0.826e0.991)
Male cases 2441 5494 0.211 0.232 0.020 0.883 (0.794e0.980)
Female hip cases 1769 5515 0.222 0.235 0.183 0.931 (0.838e1.034)
Female knee cases 1217 5515 0.215 0.232 0.014 0.903 (0.832e0.980)
Male hip cases 1270 5494 0.220 0.232 0.232 0.931 (0.828e1.047)
Male knee cases 947 5494 0.218 0.233 0.001 0.915 (0.867e0.965)
* (95% conﬁdence intervals).
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rs12595334 and rs3743342 as potential mediators of this effect.
Using the arcOGEN data we were also able to show that this eQTL
demonstrated nominal association to OA.
The allele that correlated with reduced expression of SMAD3,
the G allele of rs8031440 (indirectly tested using the perfect proxy
SNP rs7166081), was less common in the arcOGEN cases vs the
arcOGEN controls. This genetic association data therefore implies
that increased SMAD3 expression is an OA risk factor. However,
since the P-value is modest it may be sensible to interpret it with
caution at this time.
As noted in the introduction, AOS arises from rare heterozygous
SMAD3 mutations that appear to be loss-of-function4,5. Several
involve frame-shift mutations that result in nonsense-mediated
mRNA decay leading to little or no detectable transcript from the
mutant allele, whilst another leads to the substitution of arginine
for tryptophan at position 287 of the gene. This Arg287Trp muta-
tion creates a protein that is unable to form SMAD3 protein
homomers or heteromers with SMAD44. This will attenuate TGF-b
signalling. We investigated the activity of the SMAD3 eQTL in
VSMCs derived from the aortic tissue of two AOS patients, both of
whom have the Arg287Trp mutation. The eQTL was operating in
one of these patients, revealing that it is of direct relevance to this
syndrome.
AOS has a high degree of interfamilial variability4, implying that
it is likely to be inﬂuenced by the genetic background onwhich the
wild type SMAD3 allele is operating; if the wild type allele happens
to be on a low-expressing rather than a high-expressing copy of the
gene then this may lead to an even greater reduction in functional
SMAD3 and therefore a more severe phenotype. Comparing theFig. 6. Allelic expression analysis of the 3’UTR SNP rs8031440 using cDNA from
vascular smooth muscle cells. The cDNA allelic ratio in each individual was compared
to the 1:1 allelic ratio calculated from the DNA of that individual.inheritance of the eQTL between pedigrees in which AOS is segre-
gating may therefore be informative in accounting for some of the
phenotypic variability observed.
Since we have demonstrated that the SMAD3 eQTL is operating
in aortic tissue, it may also be of value to compare, at the population
level, the incidence of aneurysms between healthy individuals
homozygous for high-expressing and low-expressing alleles of the
eQTL; homozygotes for the low-expressing allele may be at greater
risk of aortic abnormalities.
Overall, our molecular study of the expression of SMAD3 has
highlighted allelic expression effects of relevance to both common
and rare forms of OA. It also supports an investigation of the in-
ﬂuence of these alleles in other conditions.
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